## SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

# **SCHEDULE 13G**

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 4)\*

# KemPharm, Inc.

(Name of Issuer)

Common Stock, \$0.0001 par value per share (Title of Class of Securities)

> 488445107 (CUSIP Number)

December 31, 2019 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

□ Rule 13d-1(b)

 $\Box$  Rule 13d-1(c)

⊠ Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1.	Names of Reporting Persons									
1.										
	Travis C. Mickle									
2.	Check the Appropriate Box if a Member of a Group (see instructions)									
	(a) 🗆 (b) 🗆									
-										
3.	SEC USE ONLY									
4.	Citize	Citizenship or Place of Organization								
	United States									
		5.	Sole Voting Power							
Number of			2,833,246 shares (1)							
Shares			Shared Voting Power							
Beneficia										
Owned by Each Reporting			419,034 shares (2)							
		7.	Sole Dispositive Power							
Persor			2,833,246 shares (1)							
With:	Ļ		Shared Dispositive Power							
			419,034 shares (2)							
9.	Aggregate Amount Beneficially Owned by Each Reporting Person									
	3,252,280 shares (1)(2)									
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)										
11.	Percent of Class Represented by Amount in Row 9									
	8.9% (3)									
12.	Type of Reporting Person (see instructions)									
	IN	IN								
L	л									

1. Consists of 1,753,117 shares of common stock held directly by Travis C. Mickle ("Dr. Mickle"), 243,880 shares of common stock held by the Christal M.M. Mickle 2015 Gift Trust u/d/p July 21, 2015, for which Dr. Mickle serves as trustee, and 836,249 shares of common stock which Dr. Mickle has the right to acquire within sixty days of December 31, 2019 upon exercise of outstanding stock options.

2. Consists of 100,604 shares of common stock held jointly with Christal M.M. Mickle ("Ms. Mickle"), 157,197 shares of common stock held by the Travis C. Mickle 2015 Dynasty Trust u/d/p July 21, 2015, for which Ms. Mickle serves as trustee, 123,217 shares of common stock held by the Mickle Family Trust u/d/p April 30, 2009, for which Dr. Mickle and Ms. Mickle serve as co-trustees, 21,466 shares of common stock held by the TCM Family Trust u/d/p April 30, 2009, for which Dr. Mickle and Ms. Mickle serve as co-trustees, and 16,550 shares of common stock held by Mickle Investments LLC, for which Dr. Mickle and Ms. Mickle serve as managing members.

3. This percentage is calculated based upon 36,350,785 shares of the Issuer's common stock outstanding as of December 31, 2019 as provided by KemPharm, Inc.

#### Item 1(a) Name of Issuer

KemPharm, Inc.

#### Item 1(b) Address of Issuer's Principal Executive Offices

1180 Celebration Boulevard, Suite 103 Celebration, FL 34747

Item 2(a) Name of Person Filing

Travis C. Mickle ("Dr. Mickle")

### Item 2(b) Address of Principal Business Office or, if none, Residence

c/o KemPharm, Inc. 1180 Celebration Boulevard, Suite 103 Celebration, FL 34747

Item 2(c) Citizenship

United States

Item 2(d) Title of Class of Securities

Common Stock, \$0.0001 par value

Item 2(e) CUSIP Number

488445107

Item 3

Not applicable.

Holder (1)	Shares Held Directly	Sole Voting Power	Shared Voting Power	Sole Dispositive Power	Shared Dispositive Power	Beneficial Ownership	Percentage of Class (1)
Travis C. Mickle	2,833,246(2)	2,833,246(2)	419,034(3)	2,833,246(2)	419,034(3)	(2) 3,252,280(3)	8.9%

(1) This percentage is calculated based upon 36,350,785 shares of the Issuer's common stock outstanding as of December 31, 2019 as disclosed by KemPharm, Inc.

(2) Consists of 1,753,117 shares of common stock held directly by Travis C. Mickle ("Dr. Mickle"), 243,880 shares of common stock held by the Christal M.M. Mickle 2015 Gift Trust u/d/p July 21, 2015, for which Dr. Mickle serves as trustee, and 836,249 shares of common stock which Dr. Mickle has the right to acquire within sixty days of December 31, 2019 upon exercise of outstanding stock options.

(3) Consists of 100,604 shares of common stock held jointly by Dr. Mickle and Christal M.M. Mickle ("Ms. Mickle"), 157,197 shares of common stock stock held by the Travis C. Mickle 2015 Dynasty Trust u/d/p July 21, 2015, for which Ms. Mickle serves as trustee, 123,217 shares of common stock held by the Mickle Family Trust u/d/p April 30, 2009, for which Dr. Mickle and Ms. Mickle serve as co-trustees, 21,466 shares of common stock held by the TCM Family Trust u/d/p April 30, 2009, for which Dr. Mickle and Ms. Mickle serve as co-trustees, and 16,550 shares of common stock held by Mickle Investments LLC, for which Dr. Mickle and Ms. Mickle serve as managing members.

#### Item 5 Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

Item 6 Ownership of More than Five Percent of Another Person

Not applicable.

Item 7 Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company.

Not applicable.

Item 8 Identification and Classification of Members of the Group

Not applicable.

Item 9 Notice of Dissolution of Group

Not applicable.

Item 10 Certification

Not applicable.

### SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

EXECUTED this 14<sup>th</sup> day of February, 2020.

/s/ Travis C. Mickle Travis C. Mickle, Ph.D.